Enfusion, Inc. (NYSE:ENFN) Sees Large Growth in Short Interest

Enfusion, Inc. (NYSE:ENFN) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 711,700 shares, an increase of 27.9% from the December 31st total of 556,500 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 695,500 shares, the short-interest ratio is presently 1.0 days.

Enfusion Price Performance

NYSE ENFN traded up $0.02 during mid-day trading on Friday, reaching $11.15. 551,512 shares of the stock were exchanged, compared to its average volume of 1,169,221. The stock has a market cap of $1.43 billion, a P/E ratio of 278.69, a P/E/G ratio of 1.82 and a beta of 0.95. Enfusion has a one year low of $7.60 and a one year high of $11.38. The stock has a 50 day simple moving average of $10.55 and a 200-day simple moving average of $9.45.

Insider Buying and Selling

In other Enfusion news, CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares in the company, valued at $2,870,036.83. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,367 shares of company stock valued at $591,335 over the last 90 days. 36.44% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. American Century Companies Inc. grew its stake in Enfusion by 17.1% during the second quarter. American Century Companies Inc. now owns 35,897 shares of the company’s stock worth $306,000 after purchasing an additional 5,253 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after buying an additional 191,436 shares during the period. Renaissance Technologies LLC increased its stake in shares of Enfusion by 167.6% in the 2nd quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock valued at $827,000 after acquiring an additional 60,811 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Enfusion during the 2nd quarter valued at $683,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Enfusion by 27.7% during the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after acquiring an additional 4,239 shares in the last quarter. 81.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on ENFN shares. Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler increased their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and an average target price of $10.50.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.